^
    Back
    Association details:
    Biomarker:ROR1 expression
    Cancer:Triple Negative Breast Cancer
    Drug:NBE-002 (DNA replication inhibitor, ROR1-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Res
    Title:

    NBE-002, an anthracycline-based immune-stimulatory antibody drug conjugate (iADC) targeting ROR1 for the treatment of triple-negative breast cancer

    Excerpt:
    Our results demonstrate that NBE-002 is a highly effective and promising targeted therapeutic for the treatment of ROR1 positive TNBC…
    DOI:
    https://doi.org/10.1158/1538-7445.AM2019-LB-197 Split-Screen Share Icon Share